Organogenesis Holdings Inc.
General ticker "ORGO" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $532.8M (TTM average)
Organogenesis Holdings Inc. follows the US Stock Market performance with the rate: 20.7%.
Estimated limits based on current volatility of 7.7%: low 2.56$, high 2.99$
Factors to consider:
- Total employees count: 869 (+0.8%) as of 2024
- Top business risk factors: Market competition, Physician support, Supply chain disruptions, Tissue supply risks, Reimbursement risks
- Earnings for 12 months up through Q4 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [2.77$, 5.45$]
- 2025-12-31 to 2026-12-31 estimated range: [2.82$, 5.52$]
Financial Metrics affecting the ORGO estimates:
- Positive: with PPE of -160.8 at the end of fiscal year the price was very low
- Positive: -4.75 < Operating profit margin, % of -0.27
- Negative: negative Industry operating cash flow (median)
- Positive: 42.68 < Shareholder equity ratio, % of 52.80 <= 64.29
- Negative: Return on assets ratio (scaled to [-100,100]) of 0.17 <= 1.87
- Positive: Inventory ratio change, % of -0.96 <= -0.75
- Positive: Industry inventory ratio change (median), % of -1.45 <= -0.16
- Positive: 0.01 < Operating cash flow per share per price, % of 3.36
- Negative: Investing cash flow per share per price, % of -2.37 <= -0.63
Short-term ORGO quotes
Long-term ORGO plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $450.89MM | $433.14MM | $482.04MM |
| Operating Expenses | $428.59MM | $420.62MM | $483.33MM |
| Operating Income | $22.30MM | $12.53MM | $-1.28MM |
| Non-Operating Income | $-2.02MM | $-2.13MM | $-1.52MM |
| Interest Expense | $2.01MM | $2.19MM | $1.54MM |
| R&D Expense | $39.76MM | $44.38MM | $50.27MM |
| Income(Loss) | $20.28MM | $10.39MM | $-2.81MM |
| Taxes | $4.75MM | $5.45MM | $-3.67MM |
| Profit(Loss)* | $15.53MM | $4.95MM | $0.86MM |
| Stockholders Equity | $265.67MM | $278.66MM | $262.90MM |
| Inventory | $24.78MM | $28.25MM | $26.22MM |
| Assets | $449.36MM | $460.02MM | $497.89MM |
| Operating Cash Flow | $24.86MM | $30.92MM | $14.21MM |
| Capital expenditure | $33.90MM | $24.36MM | $10.03MM |
| Investing Cash Flow | $-33.90MM | $-24.36MM | $-10.03MM |
| Financing Cash Flow | $-2.20MM | $-5.50MM | $27.64MM |
| Earnings Per Share** | $0.12 | $0.04 | $0.01 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.